TAS 106

Drug Profile

TAS 106

Alternative Names: ECyd; Ethynylcytidine; SB 596168; TAS-106

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics; Ribonucleosides; Small molecules
  • Mechanism of Action Antimetabolites; Cytidine triphosphate synthetase inhibitors; DNA-directed RNA polymerase inhibitors; Ribonucleotide reductase inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Head and neck cancer; Solid tumours

Most Recent Events

  • 30 Sep 2011 Phase-I/II clinical trials in Solid tumours in USA (IV)
  • 05 Jul 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Onclology (ASCO-2007) added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections ,
  • 29 Dec 2003 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top